The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications

Value in Health

Volumn 13, Issue 6, 2010, Pages 685-694

  Chapman, Richard H ^a   Kowal, Stacey L ^a   Cherry, Spencer B ^a   Ferrufino, Cheryl P ^a   Roberts, Craig S ^b   Chen, Linda ^b  

^a IQVIA   (United States)

^b PFIZER INC   (United States)

Author keywords

adherence intervention; antihypertensive; cardiovascular disease; cost effectiveness; improving adherence; lipid lowering; literature review

Indexed keywords

AMLODIPINE BESYLATE; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; HUMAN; LIFESPAN; MODEL; MONEY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SELF MONITORING;

EID: 77956370539     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00774.x     Document Type: Article

References (42)

1. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002 88 : 229 233.
2. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006 166 : 1836 1841.
3. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006 66 : 1842 1847.
4. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008 155 : 772 779.
5. World Health Organization. Adherence to long-term therapies: evidence for action. WHO. Available from: http://www.who.int/chp/knowledge/publications/ adherence-report/en/index.html [Accessed December 4, 2008 CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control. A four-year analysis of an ambulatory care model. Arch Intern Med 1984 144 : 1159 1162.
6. McKenney JM, Munroe WP, Wright JT, Jr. Impact of an electronic medication compliance aid on long-term blood pressure control. J Clin Pharmacol 1992 32 : 277 283.
7. Logan AG, Milne BJ, Achber C, et al. Work-site treatment of hypertension by specially trained nurses. A controlled trial. Lancet 1979 2 : 1175 1178.
8. Logan AG, Milne BJ, Achber C, et al. Cost-effectiveness of a worksite hypertension treatment program. Hypertension 1981 3 : 211 218.
9. Monson R, Bond CA, Schuna A. Role of the clinical pharmacist in improving drug therapy. Clinical pharmacists in outpatient therapy. Arch Intern Med 1981 141 : 1441 1444.
10. Faulkner MA, Wadibia EC, Lucas BD, et al. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000 20 : 410 416.
11. Friedman RH, Kazis LE, Jette A, et al. A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Am J Hypertens 1996 9 : 285 292.
12. Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976 1 : 1265 1268.
13. Skaer TL, Sclar DA, Markowski DJ, et al. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. J Hum Hypertens 1993 7 : 515 518.
14. Skaer TL, Sclar DA, Robison LM, et al. Effect of pharmaceutical formulation for antihypertensive therapy on health service utilization. Clin Ther 1993 15 : 715 725.
15. Márquez-Contreras E, Martell-Claros N, Gil-Guillén V, et al. Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. J Hypertens 2006 24 : 169 175.
16. Ali F, Laurin MY, Lariviere C, et al. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol 2003 10 : 101 106.
17. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006 296 : 2563 2571.
18. Saunders LD, Irwig LM, Wilson TD. Hypertension management and patient compliance at a Soweto polyclinic. S Afr Med J 1982 61 : 147 151.
19. Chapman RH, Ferrufino C, Kowal S, et al. The cost and effectiveness of adherence improving interventions for antihypertensive and lipid-lowering drugs. Int J Clin Pract 2010 64 : 169 181.
20. Cherry SB, Benner JS, Hussein MA, et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health 2009 12 : 489 497.
21. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002 288 : 455 461.
22. Cardinal H, Monfared AA, Dorais M, et al. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. Can J Cardiol 2004 20 : 417 421.
23. Petrilla AA, Benner JS, Battleman DS, et al. Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications. Int J Clin Pract 2005 59 : 1441 1451.
24. U.S. Department of Labor Bureau of Labor and Statistics. US Medical Care Consumer Price Index, All Urban Consumers. CUUR0000SAM. 2006. Available from: http://data.bls.gov/cgi-bin/surveymost?cu [Accessed June 1, 2009 PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 361 : 1149 1158.
25. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007 10 : 3 12.
26. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008 11 : 44 7.
27. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005 165 : 1147 1152.
28. Benner JS, Chapman RH, Petrilla AA, et al. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm 2009 66 : 1471 1477.
29. Donnelly LA, Doney AS, Morris AD, et al. Long-term adherence to statin treatment in diabetes. Diabet Med 2008 25 : 850 855.
30. LaFleur J, Thompson CJ, Joish VN, et al. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother 2006 40 : 1274 1279.
31. Nichol MB, Knight TK, Wu J, et al. Transition probabilities and predictors of adherence in a California Medicaid population using antihypertensive and lipid-lowering medications. Value Health 2009 12 : 544 550.
32. Gold MR, Slegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York : Oxford University Press, 1996.
33. Brunenberg DE, Wetzels GE, Nelemans PJ, et al. Cost effectiveness of an adherence-improving programme in hypertensive patients. Pharmacoeconomics 2007 25 : 239 251.
34. Benner JS, Pollack MF, Smith TW, et al. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005 62 : 1468 1475.
35. Fletcher B, Berra K, Ades P, et al. Managing abnormal blood lipids: a collaborative approach. Circulation 2005 112 : 3184 3209.
36. Thomas TS. Improving care with nurse case managers: practical aspects of designing lipid clinics. Am J Cardiol 1997 80 : 62H 5H.
37. Schectman G, Wolff N, Byrd JC, et al. Physician extenders for cost-effective management of hypercholesterolemia. J Gen Intern Med 1996 11 : 277 286.
38. Schraeder C, Fraser C, Clark I, et al. The effect of primary care management on lipids testing and LDL-C control of elderly patients with comorbidities. Prof Case Manag 2009 14 : 84 95.
39. Greenland P. Closing the treatment gap: in the community and at hospital discharge. Am J Med 1996 101 : 4A76S 78S.
40. Schroeder K, Fahey T, Hollinghurst S, et al. Nurse-led adherence support in hypertension: a randomized controlled trial. Fam Pract 2005 22 : 144 151.
41. Lindgren P, Buxton M, Kahan T, et al. The lifetime cost-effectiveness of amlodipine-based therapy + atorvastatin compared to atenolol + atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Pharmacoeconomics 2009 27 : 221 230.
42. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006 333 : 15.